Paul Hartmann AG (FRA:PHH2) Risk Assessment

View and export this data going back to . Start your Free Trial

What is Paul Hartmann AG Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Paul Hartmann AG is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Paul Hartmann AG's Risk Assessment

For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paul Hartmann AG's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Paul Hartmann AG's Risk Assessment falls into.

Paul Hartmann AG (FRA:PHH2) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Paul Hartmann AG Risk Assessment Related Terms

Thank you for viewing the detailed overview of Paul Hartmann AG's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Paul Hartmann AG (FRA:PHH2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Paul Hartmann AG (FRA:PHH2) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

PHH2:Germany

Address

Paul-Hartmann-Strasse 12, Heidenheim, DEU, 89522

Website

http://www.hartmann.info

Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.

Executives

Eduard Schleicher	Supervisory Board
Britta Fünfstück	Board of Directors

Paul Hartmann AG (FRA:PHH2) Headlines

No Headlines